Rohto Pharmaceutical


The Rohto Pharmaceutical Co., Ltd. is a multinational fast-moving consumer goods and OTC pharmaceutical corporation headquartered in Ikuno-ku, Osaka, Japan, with a presence in North America, Europe and Asia. The company is listed on the stock exchange having posted steady increases in revenues from ¥95,619 million in 2006 to ¥120,292 million in 2011. Skin Care contributes to 61.3% of the revenues while Eye Care contributes to 21% of their sales.

Market Segments

Rohto is active in the three consumer segments of:
In 1974, Rohto set its eyes on The Mentholatum Company. In August 1975, it acquired the trademark rights to Mentholatum and began to sell the Mentholatum Ointment and Mentholatum Medicated Lip Stick, which proved to be a financial success as the company's revenue skyrocketed to ¥2.64 billion by April 1981. Rohto Pharmaceutical Co. continued to acquire the management rights to The Mentholatum Company Inc in June 1988, thus completing the merge.
Rohto group has established operations in 15 major markets, with marketing/distribution agreements in more than 150 countries globally. They have two production plants in Japan and 6 production plants across US, UK, China, Vietnam, Hong Kong and Indonesia.
Rohto entered the Vietnam market in 1997 and set up their manufacturing base to cater to the Asia Pacific market. In mid-2010, Rohto entered the India market and started operations in the lipcare and skin care segment, with their internationally popular brands, Lipice and Oxy. Simultaneously they also entered the Bangladesh market.
With a strong presence across international markets, the company has a manpower strength of close to 5000 employees.
Yasutami Yamada founded "Shintendo, Yasutami Yamada Pharmaceutical Company", the predecessor of Rohto, in Shimizucho, Higashi-ku, Osaka on February 22, 1899. Yamada sold "Rohto Eyedrops" in 1909. "Rohto" was named after August von Rothmund, a German ophthalmologist who was a professor for Toyotaro Inoue, a Japanese ophthalmologist.

Brands